---
title: "Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Long-term prophylaxis"
description: "Formulary evidence on Deucrictibant (PHA121, PHA-022121) in On-demand treatment of hereditary angioedema attacks: Long-term prophylaxis. Topics: First-line long-term prophylaxis options: guideline recommendations, Subcutaneous plasma-derived C1 inhibitor: indication and dosing, Intravenous plasma-derived C1 inhibitor: indication and dosing, Lanadelumab: indication and dosing interval, and 13 further topics. 17 evidence topics quoted from 17 sources."
canonical: "https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description/long-term-prophylaxis"
published: "2026-11-18T22:35:03-05:00"
modified: "2026-11-18T22:35:03-05:00"
---

# Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Long-term prophylaxis

<a id="heading-2.2.2.1.4"></a>

## 2.2.2.1.4 Long-term Prophylaxis

<a id="topic-2.2.2.1.4-1"></a>

### First-line long-term prophylaxis options: guideline recommendations

> “We recommend SC pdC1-INH, lanadelumab, berotralstat, garadacimab, or donidalorsen as first-line options for LTP.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

> “Berotralstat, donidalorsen, garadacimab, lanadelumab, or pdC1INH could be used as first-line therapy for long-term prophylaxis in patients with HAE due to C1INH deficiency.”

Source: [Betschel et al. (2026)](https://link.springer.com/article/10.1186/s13223-025-00999-8)

<a id="topic-2.2.2.1.4-2"></a>

### Subcutaneous plasma-derived C1 inhibitor: indication and dosing

> “HAEGARDA is a plasma-derived concentrate of C1 Esterase Inhibitor (Human) (C1-INH) indicated for routine prophylaxis to prevent Hereditary Angioedema (HAE) attacks in patients 6 years of age and older.”
> “Administer 60 International Units per kg body weight twice weekly (every 3 or 4 days).”

Source: [CSL Behring (2022)](https://labeling.cslbehring.com/PI/US/HAEGARDA/EN/HAEGARDA-Prescribing-Information.pdf)

<a id="topic-2.2.2.1.4-3"></a>

### Intravenous plasma-derived C1 inhibitor: indication and dosing

> “CINRYZE is a C1 esterase inhibitor indicated for routine prophylaxis against angioedema attacks in adults, adolescents, and pediatric patients (6 years of age and older) with Hereditary Angioedema (HAE).”
> “1,000 IU Intravenous every 3 or 4 days”
> “Doses up to 2,000 IU (not exceeding 80 IU/kg) every 3 or 4 days may be considered based on individual patient response.”

Source: [FDA (2022)](https://www.fda.gov/media/75907/download)

<a id="topic-2.2.2.1.4-4"></a>

### Lanadelumab: indication and dosing interval

> “TAKHZYRO is a plasma kallikrein inhibitor (monoclonal antibody) indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 2 years and older.”
> “The recommended starting dosage in adult and pediatric patients 12 years of age and older is 300 mg administered subcutaneously every 2 weeks (q2wks).”
> “A dosing interval of 300 mg every 4 weeks (q4wks) is also effective and may be considered if the patient is well-controlled (e.g., attack free) for more than 6 months.”

Source: [FDA TAKHZYRO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761090s020lbl.pdf)

<a id="topic-2.2.2.1.4-5"></a>

### Berotralstat: oral prophylaxis and dosing

> “ORLADEYO is a plasma kallikrein inhibitor indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 2 years and older.”
> “The recommended dosage of ORLADEYO for adults and pediatric patients 12 years of age and older is 150 mg taken orally once daily with food”
> “ORLADEYO should not be used for treatment of acute HAE attacks.”

Source: [FDA ORLADEYO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/214094s006lbl.pdf)

<a id="topic-2.2.2.1.4-6"></a>

### Garadacimab: mechanism, population, and dosing

> “Garadacimab-gxii is an inhibitor of activated FXII”
> “an initial loading dose of 400 mg”
> “200 mg administered subcutaneously every month.”
> “ANDEMBRY is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.”
> “ANDEMBRY is intended for self-administration or administration by a caregiver.”

Source: [FDA ANDEMBRY prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761367s000lbl.pdf)

<a id="topic-2.2.2.1.4-7"></a>

### Donidalorsen: indication, mechanism, and dosing

> “DAWNZERA is a prekallikrein-directed antisense oligonucleotide indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older.”
> “The recommended dosage of DAWNZERA is 80 mg administered subcutaneously every 4 weeks.”
> “A dosage of 80 mg administered subcutaneously every 8 weeks may be considered.”
> “Donidalorsen lowers PKK concentration, preventing excessive bradykinin production in patients with HAE.”

Source: [FDA DAWNZERA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219407s000lbl.pdf)

<a id="topic-2.2.2.1.4-8"></a>

### Lanadelumab and berotralstat: guideline summary of efficacy

> “Lanadelumab, a fully human monoclonal antibody directed against plasma kallikrein, reduces the risk of attacks in the context of LTP, with a low risk of adverse events and a positive impact on QoL.”
> “Reported attack rates with this drug are less than 0.3 per month with biweekly dosing, and over 95% of treatment-emergent adverse events are non-serious.”
> “Berotralstat, an oral plasma kallikrein inhibitor, demonstrated efficacy in a pivotal trial, achieving a ∼50% reduction in attack rate.”
> “Patients should be aware of delayed onset of action.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.2.1.4-9"></a>

### Attenuated androgens: second-line prophylaxis

> “We recommend the use of androgens only as second-line long-term prophylaxis.”

Source: [Maurer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9023902/)

> “We suggest IV C1-INH, attenuated androgens (at the lowest effective dose, preferably not exceeding 200 mg per day), or antifibrinolytics as second-line options for LTP in patients for whom first-line therapies are not available, not feasible, or not tolerated.”
> “Attenuated androgens are strongly associated with virilization in women, dyslipidemia, and hepatotoxicity, with an increased risk of hepatic neoplasms.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.2.1.4-10"></a>

### Deucrictibant extended-release tablet for prophylaxis: CHAPTER-3 phase 3 results (investigational)

> “CHAPTER-3 (NCT06669754) met the primary endpoint and all secondary efficacy endpoints with statistical significance.”
> “Treatment with deucrictibant XR in participants with all types of HAE reduced the mean monthly attack rate by 83% (p<0.0001)”
> “Preparation of NDA dossier of deucrictibant XR for prophylaxis of AE-BK attacks ongoing; timeline remains on-track for submission in 1H2027”

Source: [Pharvaris Form 6-K, third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_1.htm)

<a id="topic-2.2.2.1.4-11"></a>

### Attacks during prophylaxis and continued access to on-demand treatment: guideline statements

> “Attacks can still occur even in patients under LTP, and on-demand medication must remain available to them.”
> “We recommend that patients have access to ODT, even while receiving LTP.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

> “Although the aim of LTP is to reduce the number and severity of attacks, it does not completely eliminate the risk of attacks.”
> “All patients must have a plan for on-demand treatment of attacks and have at least two doses of acute treatments available even while on LTP therapy.”

Source: [Betschel et al. (2026)](https://link.springer.com/article/10.1186/s13223-025-00999-8)

> “We recommend supplying all pediatric patients with hereditary angioedema with acute treatment for at least two angioedema attacks even if they are on long‐term prophylaxis.”

Source: [Farkas et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466006/)

<a id="topic-2.2.2.1.4-12"></a>

### Attacks and on-demand treatment use during prophylaxis: systematic review of 45 studies

> “Forty-five primary studies met the inclusion criteria.”
> “In phase 3 trials, attack-free rates were 40% for subcutaneous pdC1INH 60 IU/kg twice weekly at 16 weeks, and 44% for lanadelumab 300 mg every second week at 6 months (77% during steady-state [days 70–182]); there was no difference in attack-free rate for berotralstat 150 mg versus placebo at 24 weeks.”
> “Laryngeal attacks accounted for 2%-7% of all attacks in observational and interventional studies, regardless of the LTP agent received.”
> “On-demand therapy was used in 49%-94% of attacks occurring in the presence of LTP.”

Source: [Longhurst et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11638394/)

<a id="topic-2.2.2.1.4-13"></a>

### Persistence, switching, and on-demand use after starting prophylaxis: US claims

> “This study found that 55% of patients had refill gaps in LTP claims, discontinued, or switched LTP within a year of initiation.”
> “Even with use of LTP, on-demand treatment utilization remained present for over two-thirds of patients.”

Source: [Tachdjian et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13273463/)

<a id="topic-2.2.2.1.4-14"></a>

### On-demand prescriptions after starting subcutaneous prophylaxis: US claims

> “Study population included 196 patients (C1-INH-SC: N=65; lanadelumab: N=131); mean age was 39 years and 69% were female.”
> “Mean annualized number of ODT prescriptions was 3.8 (3.6–4.1) per patient”

Source: [Kutrieb et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13151981/)

<a id="topic-2.2.2.1.4-15"></a>

### On-demand rescue medication during intravenous C1 inhibitor prophylaxis: US claims

> “There were 306 episodes of prophylactic use of C1-INH(IV) (defined by continuous refills averaging ≥1500 IU/week for ≥13 weeks) in 155 patients; use of ≥1 on-demand rescue medication was implicated during 53% (163/306) of those episodes.”

Source: [Riedl et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6186115/)

<a id="topic-2.2.2.1.4-16"></a>

### On-demand dispensing during lanadelumab or berotralstat prophylaxis: Swedish national register

> “Among patients with ≥12 months on modern LTP (n=69) who had at least one ODT dispensation event during their most recent 12 months of treatment (n=46/59 for lanadelumab; n=8/9 for berotralstat), the mean number of ODT packages dispensed”
> “in addition to emergency stock ODT”
> “was 4.3 per patient on lanadelumab and 6.5 per patient on berotralstat.”
> “Overall, 22% (n=15/69) of patients receiving modern LTP did not dispense ODT medication during their most recent 12-months of treatment.”

Source: [Meisgen et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13461400/)

<a id="topic-2.2.2.1.4-17"></a>

### Breakthrough attack rate during prophylaxis: KONFIDENT-S interim analysis

> “As of September 14, 2024, 35 participants receiving LTP experienced a mean ± standard deviation of 1.7 ± 1.5 attacks per month and treated 382 attacks with sebetralstat (1.3 ± 1.1 sebetralstat-treated attacks per month).”

Source: [Kinaciyan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13355760/)

## Related pages
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references.md)
